Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Pdl Biopharma Inc (PDLI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 424,435
  • Shares Outstanding, K 154,340
  • Annual Sales, $ 244,300 K
  • Annual Income, $ 63,610 K
  • 36-Month Beta 0.45
  • Price/Sales 1.40
  • Price/Cash Flow 6.64
  • Price/Book 0.51

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.72 +2.57%
on 01/19/18
3.03 -7.92%
on 12/20/17
-0.21 (-7.00%)
since 12/19/17
3-Month
2.70 +3.33%
on 11/15/17
3.55 -21.41%
on 10/23/17
-0.70 (-20.06%)
since 10/19/17
52-Week
1.96 +42.35%
on 03/24/17
3.55 -21.41%
on 10/23/17
+0.43 (+18.22%)
since 01/19/17

Most Recent Stories

More News
Look for Shares of Pdl Biopharma In to Potentially Rebound after Yesterday's 1.90% Sell Off

Pdl Biopharma In (NASDAQ:PDLI) traded in a range yesterday that spanned from a low of $2.83 to a high of $2.92. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $2.86...

PDLI : 2.79 (+1.45%)
PDL BioPharma, Inc. (PDLI) Jumps: Stock Rises 8.2%

PDL BioPharma, Inc, (PDLI) was a big mover last session, as the company saw its shares more than 8% on the day amid huge volumes.

PTGX : 18.99 (-0.26%)
PDLI : 2.79 (+1.45%)
PDL BioPharma, Inc. (PDLI) Jumps: Stock Rises 8.2%

PDL BioPharma, Inc. (PDLI) was a big mover last session, as the company saw its shares more than 8% on the day amid huge volumes.

PTGX : 18.99 (-0.26%)
PDLI : 2.79 (+1.45%)
Noden Pharma Announces FDA Approval of Tekturna®(aliskiren) Oral Pellets for the Treatment of Hypertension in Adults and Children 6 Years of Age and Older

Noden Pharma DAC, a global specialty pharmaceutical company that is focused on acquiring prescription medicines across a broad range of therapeutic areas, announced today the approval by the U.S. Food...

PDLI : 2.79 (+1.45%)
AstraZeneca Gets Positive CHMP Opinion for Asthma Candidate

AstraZeneca (AZN) received CHMP recommendation for marketing approval of its pipeline candidate, benralizumab for treating severe eosinophilic asthma.

LGND : 155.81 (+3.49%)
PDLI : 2.79 (+1.45%)
AZN : 35.44 (+1.06%)
JNJ : 147.36 (+0.30%)
Puma (PBYI) Falls Despite Narrower-Than-Expected Q3 Loss

Puma Biotechnology (PBYI) reported narrower-than-expected loss in Q3. However, shares were down in after-hours trading.

LGND : 155.81 (+3.49%)
PDLI : 2.79 (+1.45%)
PBYI : 91.60 (+3.80%)
RHHBY : 30.6900 (+0.59%)
Factors of Influence in 2018, Key Indicators and Opportunity within Tegna, Inpixon, Honeywell International, Nektar, PDL Biopharma, and Innoviva - New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tegna Inc. (NYSE:TGNA), Inpixon...

TGNA : 15.14 (+0.73%)
INVA : 14.83 (+3.20%)
PDLI : 2.79 (+1.45%)
HON : 158.69 (+0.58%)
INPX : 0.41 (+5.13%)
NKTR : 71.59 (+2.04%)
PDL BioPharma to Present at Two Upcoming Investor Conferences

PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, PDL's president and chief executive officer, will present at two investor conferences in November.

PDLI : 2.79 (+1.45%)
PDL BioPharma (PDLI) Q3 Earnings Beat, Revenues Rise Y/Y

PDL BioPharma's (PDLI) earnings top estimates in Q3. Revenues also grow year over owing to rise in royalty rights.

LGND : 155.81 (+3.49%)
PDLI : 2.79 (+1.45%)
VRX : 21.52 (-2.62%)
BIIB : 342.41 (-0.59%)
PDL BioPharma Announces Third Quarter 2017 Financial Results

PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today reported financial results for the third quarter ended September 30, 2017 including:

PDLI : 2.79 (+1.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Protein Design Labs Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital...

See More

Key Turning Points

2nd Resistance Point 2.84
1st Resistance Point 2.82
Last Price 2.79
1st Support Level 2.74
2nd Support Level 2.69

See More

52-Week High 3.55
Fibonacci 61.8% 2.94
Last Price 2.79
Fibonacci 50% 2.76
Fibonacci 38.2% 2.57
52-Week Low 1.96

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.